Back to first-pass browser

First-pass extracted concept

autologous HSC gene therapy

Candidate: concept label1 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This approach modifies a patient's own hematopoietic stem cells using lentiviral gene addition or silencing and CRISPR-based gene editing. The abstract frames it as a route toward curative therapy for sickle cell disease.

Source 1DOIPubMed

Resources required

The established approach requires collection and ex vivo culture of HSCs before gene modification. It also depends on a gene-modification modality such as lentiviral engineering or CRISPR editing.

Source 1DOIPubMed

What problem it solves

It addresses the donor-availability limitation of allogeneic HSC transplantation by using autologous cells. The abstract also presents it as a way to make gene therapy applicable to most patients.

Source 1DOIPubMed

What it does not solve

The abstract states that the established ex vivo method remains costly and complex. It does not claim that this approach removes the need for ex vivo handling.

Source 1DOIPubMed

Alternatives

The abstract contrasts this approach with hydroxyurea, allogeneic HSC transplantation, and emerging in vivo HSC gene therapy.

Source 1DOIPubMed

Evidence Snippets

autologous HSC gene therapy was developed using patients' own HSCs with lentiviral gene addition/silencing and clustered regularly interspaced short palindromic repeats gene editing, making gene therapy applicable to most patients
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1comparative therapysupports2025Source 1DOIPubMed

Allogeneic HSC transplantation is a one-time curative treatment for sickle cell disease but is limited by availability of histocompatible donors.

Quoted textsource-backed
Allogeneic HSC transplantation is a one-time, curative treatment for SCD with limited availability of histocompatible donors.
Claim 2comparative therapysupports2025Source 1DOIPubMed

Hydroxyurea is a first-line drug therapy for sickle cell disease but requires lifelong administration.

Quoted textsource-backed
Several drug therapies are available for SCD, including hydroxyurea, which is the first-line choice despite requiring lifelong administration.
Claim 3disease suitabilitysupports2025Source 1DOIPubMed

Sickle cell disease is a prime candidate for gene therapy because it is a common single-gene disorder.

Quoted textsource-backed
Sickle cell disease is one of the most common single-gene disorders; therefore, SCD is a prime candidate for gene therapy.
Claim 4limitationsupports2025Source 1DOIPubMed

The established method of HSC gene therapy requires costly and complex ex vivo HSC culture.

Quoted textsource-backed
the established method of HSC gene therapy requires costly and complex ex vivo HSC culture
Claim 5modality descriptionsupports2025Source 1DOIPubMed

Autologous HSC gene therapy for sickle cell disease uses patients' own HSCs with lentiviral gene addition or silencing and CRISPR gene editing, making gene therapy applicable to most patients.

Quoted textsource-backed
autologous HSC gene therapy was developed using patients' own HSCs with lentiviral gene addition/silencing and clustered regularly interspaced short palindromic repeats gene editing, making gene therapy applicable to most patients
Claim 6therapeutic rationalesupports2025Source 1DOIPubMed

DNA-level correction of hematopoietic stem cells can enable a one-time cure of genetic diseases including sickle cell disease.

Quoted textsource-backed
DNA-level correction of HSCs allows for a one-time cure of genetic diseases, including sickle cell disease (SCD).